Vioxx and Bextra are off the shelves. Celebrex can't be far behind. What happened? That is beginning to become clear, but the next question is what are the pharmas going to do about it? What does this mean for R&D, profits, marketing, and taking chances? John Mack is trying not to gloat and saying "I told you so..." but well he did have a point--Pharma Marketing Blog- Cox-2's (and Pfizer?) on Slippery Slope.
What do you think pharma's solution should be? And what's next?
Powered By Qumana
Syndicate Biopeer
